Glenmark Pharmaceuticals’ subsidiary Glenmark Specialty S.A. has entered into an exclusive licensing agreement with Seqirus, part of Australia-based specialty biotechnology company CSL, to commercialize Ryaltris in Australia and New Zealand.
Ryaltris (olopatadine hydrochloride (665 mcg) and mometasone furoate (25 mcg)) is a novel, investigational, fixed-dose combination nasal spray of an antihistamine and a steroid, indicated for treatment of symptoms associated with seasonal allergic rhinitis (SAR) in patients over 12 years of age.
Under the terms of the agreement, Glenmark will be responsible for product supply and Seqirus will be responsible for regulatory filing and commercialization of the product in Australia and New Zealand.
Glenmark will receive an upfront payment as well as regulatory and commercial milestone payments from Seqirus.
Glenmark Pharmaceuticals is a global pharmaceutical company. The company is engaged in the development of new chemical entities (NCEs) and new biological entities (NBEs). Its segments are India, United States, Latin America, Europe and Rest of the World (ROW).
